Hohenberger P
Sektion Chirurgische Onkologie und Thoraxchirurgie, Chirurgische Universitätsklinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1, Mannheim, Germany.
Radiologe. 2009 Dec;49(12):1122-7. doi: 10.1007/s00117-009-1853-8.
Gastro-intestinal stromal tumors (GIST) form the commonest subgroup of soft tissue sarcomas. They arise in the muscular layer of the esophagus, stomach, small intestines and rectum. Characteristic and important for the assessment of the extent of tumors is the peripheral rim vascularization of primary tumors and metastases. Indications for resection are given for tumors larger than 2 cm in size. Locally advanced GISTs can be advantageously treated with imatinib/sunitinib as neoadjuvant and it is often possible to select a low level of resection for this size of tumor and when the rim area is not hypervascularized. Even in the metastasizing stage surgical treatment can be used for elimination of resistant metastases or for removal of residual tumor tissue in an attempt to counteract secondary tumor progression. The effect of this treatment is currently being tested in a randomized phase III study.
胃肠道间质瘤(GIST)是软组织肉瘤中最常见的亚组。它们起源于食管、胃、小肠和直肠的肌层。原发性肿瘤和转移灶的外周边缘血管形成对于评估肿瘤范围具有特征性且很重要。对于直径大于2 cm的肿瘤,有手术切除指征。局部进展期GIST可采用伊马替尼/舒尼替尼作为新辅助治疗,对于这种大小的肿瘤且边缘区域无血管过度增生时,通常有可能选择低水平的切除。即使在转移阶段,手术治疗也可用于消除耐药转移灶或切除残留肿瘤组织,以试图对抗继发性肿瘤进展。目前正在一项随机III期研究中测试这种治疗的效果。